


Mortality Risk According to CRF and RAAS-I Interaction

Presented at the American Heart Association Annual Meeting, Nov 15-18 2019



Dr. Kokkinos found:

1. Significantly lower mortality risk in patients treated with renin-angiotensin-aldosterone system inhibitors (RAAS-I) compared to those not treated.
2. The association between fitness and mortality risk was independent, inverse and followed a dose-response pattern in those treated and not treated with RAAS-I.
3. The combination of the RAAS-I and fitness resulted in lower mortality risk than either therapy alone!